Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04260464 · ClinicalTrials.gov registry record · Phase 1
Renal Impairment Study of PF-06700841
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT04260464 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 30 participants.
The verdict
NCT04260464, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the effect of kidney impairment on the blood concentrations of PF-06700841 and its major metabolite. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of kidney disease.
Interventions
- DRUG PF-06700841
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-07-03 |
| Est. Completion | 2022-05-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04260464
The ClinicalTrials.gov registry entry for NCT04260464 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06700841 is the first listed.
NCT04260464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04260464 about?
NCT04260464 is a clinical study titled "Renal Impairment Study of PF-06700841". The purpose of this study is to characterize the effect of kidney impairment on the blood concentrations of PF-06700841 and its major metabolite. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the prese...
What is the current status of trial NCT04260464?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-07-03. Estimated completion is 2022-05-04.
What interventions are being tested in trial NCT04260464?
The interventions under investigation include: PF-06700841 (DRUG).
Who is sponsoring clinical trial NCT04260464?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.